Bank of Montreal Can Reduces Stock Holdings in Genmab A/S (NASDAQ:GMAB)

Bank of Montreal Can cut its stake in shares of Genmab A/S (NASDAQ:GMAB) by 1.5% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 75,819 shares of the company’s stock after selling 1,168 shares during the period. Bank of Montreal Can’s holdings in Genmab A/S were worth $1,845,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GMAB. DDD Partners LLC purchased a new stake in shares of Genmab A/S during the second quarter worth about $8,860,000. Cubist Systematic Strategies LLC grew its stake in Genmab A/S by 109.7% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock valued at $7,000,000 after purchasing an additional 145,689 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Genmab A/S by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after purchasing an additional 103,859 shares during the last quarter. Sanctuary Advisors LLC acquired a new position in shares of Genmab A/S in the 2nd quarter valued at approximately $1,354,000. Finally, Ingalls & Snyder LLC boosted its stake in shares of Genmab A/S by 29.3% during the 2nd quarter. Ingalls & Snyder LLC now owns 229,700 shares of the company’s stock valued at $5,772,000 after buying an additional 52,117 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Up 0.9 %

GMAB opened at $21.85 on Friday. The company’s 50-day moving average price is $22.46 and its 200 day moving average price is $25.41. Genmab A/S has a fifty-two week low of $20.34 and a fifty-two week high of $32.88. The firm has a market cap of $14.46 billion, a price-to-earnings ratio of 21.21, a price-to-earnings-growth ratio of 0.67 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The company had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. During the same quarter in the previous year, the company posted $0.47 earnings per share. Research analysts anticipate that Genmab A/S will post 1.3 earnings per share for the current year.

Wall Street Analyst Weigh In

GMAB has been the subject of a number of research analyst reports. Truist Financial dropped their price target on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, September 9th. Redburn Atlantic started coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They issued a “buy” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Wednesday, October 16th. Morgan Stanley reissued an “equal weight” rating and issued a $31.00 price objective on shares of Genmab A/S in a report on Wednesday, September 11th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Genmab A/S in a report on Tuesday, August 20th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Genmab A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.